Rebranding of generic parenteral vasopressin: Effect on clinician practices and perceptions

被引：10

作者：

Curtis, Nicole ^{[1
]}

Corapi, Jennifer ^{[1
]}

Roberts, Russel ^{[2
]}

Devlin, John W. ^{[1
]}

机构：

[1] Northeastern Univ, Sch Pharm, Boston, MA 02115 USA

[2] Massachusetts Gen Hosp, Dept Pharm Serv, Boston, MA 02114 USA

来源：

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY | 2017年 / 74卷 / 03期

关键词：

drug cost; generic rebranding; intensive care; severe sepsis; vasopressin;

D O I：

10.2146/ajhp160460

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：105 / 106

页数：2

共 6 条

[1] The costs of prescription drugs in the United States: Pharmacists' voices must be heard [J].

Abramowitz, Paul W. ;

Cobaugh, Daniel J. .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (08) :515-516

[2]

[Anonymous], RED BOOK ONL DAT

[3]

[Anonymous], DRUG INFORM HDB

[4]

[Anonymous], OFFICIALS QUESTION R

[5]

Dellinger RP, 2013, INTENS CARE MED, V39, P165, DOI [10.1007/s00134-012-2769-8, 10.1097/CCM.0b013e31827e83af]

[6] Vasopressin versus norepinephrine infusion in patients with septic shock [J].

Russell, James A. ;

Walley, Keith R. ;

Singer, Joel ;

Gordon, Anthony C. ;

Hebert, Paul C. ;

Cooper, D. James ;

Holmes, Cheryl L. ;

Mehta, Sangeeta ;

Granton, John T. ;

Storms, Michelle M. ;

Cook, Deborah J. ;

Presneill, Jeffrey J. ;

Ayers, Dieter .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (09) :877-887

← 1 →